What is the efficacy of everolimus for the treatment of renal cell carcinoma (RCC)?

Updated: Feb 19, 2021
  • Author: Kush Sachdeva, MD; Chief Editor: E Jason Abel, MD  more...
  • Print

In a randomized, double-blind, placebo-controlled, multicenter, phase 3 trial in patients with metastatic renal cell carcinoma that had progressed during sunitinib and/or sorafenib treatment, analysis showed significantly longer median progression-free survival with everolimus than with placebo. [46, 47] The median overall survival with everolimus was 14.8 months compared with 14.4 months for placebo; 80% of patients in the placebo arm crossed over to everolimus. [46]

A pooled analysis of four prospective, non-interventional studies provided evidence that everolimus can be safe and effective for second-line treatment of metastatic renal cell carcinoma refractory to anti-VEGF therapy. In the analysis, which included a total of 632 patients in whom one or two anti-VEGF therapies had failed, median time to progression was 6.3 months for the overall study population and 6.4 months for patients treated with second-line everolimus. Median progression-free survival was 5.5 months for the overall population and 5.8 months for the everolimus group. [48]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!